‘Thaw-and-inject’ cells given to new groups in Parkinson’s trial
Aspen Neuroscience has expanded its ongoing Phase 1/2a clinical trial by dosing two new groups of Parkinson’s disease patients with sasineprocel (ANPD001). For the first time in the study, these…